{"filing":{"accession_number":"0001837607-26-000061","cik":"0001837607","ticker":"AEON","company_name":"AEON Biopharma, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"aeon-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812x8k.htm"},"events":[{"id":27223,"run_id":24798,"accession_number":"0001837607-26-000061","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"AEON Biopharma disclosed its second quarter 2026 financial results on August 12, 2026, reporting a net loss of $12.9 million for the six months ended June 30, 2026, a cash position of $3.4 million, and a $15.3 million financing with milestone warrants.","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28658,"accession_number":"0001837607-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AEON Biopharma disclosed its second quarter 2026 financial results on August 12, 2026, via a press release furnished as Exhibit 99.1. The filing includes condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026, showing a net loss of $12.9 million for the six months ended June 30, 2026. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:46.396561+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28659,"accession_number":"0001837607-26-000061","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes a press release (Exhibit 99.1) reporting AEON's second quarter 2026 financial results, including cash position ($3.4M as of June 30, 2026), operating losses, and a $15.3M financing with milestone warrants. The press release explicitly states \"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update,\" making this a quarterly earnings disclosure. While Item 7.01 is technically a catch-all for other events, the substance here is the earnings release, which is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:46.396561+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28658,"accession_number":"0001837607-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AEON Biopharma disclosed its second quarter 2026 financial results on August 12, 2026, via a press release furnished as Exhibit 99.1. The filing includes condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026, showing a net loss of $12.9 million for the six months ended June 30, 2026. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:46.396561+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-12"},{"id":28659,"accession_number":"0001837607-26-000061","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes a press release (Exhibit 99.1) reporting AEON's second quarter 2026 financial results, including cash position ($3.4M as of June 30, 2026), operating losses, and a $15.3M financing with milestone warrants. The press release explicitly states \"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update,\" making this a quarterly earnings disclosure. While Item 7.01 is technically a catch-all for other events, the substance here is the earnings release, which is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:20:46.396561+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-12"}]}